US-based genetic testing company GeneDx has closed its previously announced acquisition of Fabric Genomics, a biotechnology firm specialising in AI-powered genomic interpretation.
Last month, GeneDx announced its plans to acquire Fabric Genomics to expand its addressable market with multiple scalable revenue streams.
The strategic acquisition combines centralised and decentralised models to deliver clinically actionable genomic insights on a global scale.
It will integrate GeneDx’s expertise in exome and genome testing with Fabric Genomics’ advanced AI interpretation services to establish a new ecosystem for genomic diagnostics.
The integrated model offers enhanced flexibility for providers and health systems, facilitating seamless workflow integration for both centralised and decentralised genomic services.
Fabric Genomics will continue to operate independently as a subsidiary of GeneDx.
GeneDx president and CEO Katherine Stueland said: “Healthcare is at an inflection point where genomic insights must be integrated into standard care to improve outcomes and reduce costs.
“With Fabric Genomics now part of GeneDx, we’re uniquely positioned to deliver earlier and more accurate diagnoses worldwide, from NICUs and pioneering newborn screening programs to health systems across the globe.”
The acquisition advances several key growth opportunities for GeneDx, including neonatal intensive care unit (NICU) genomic testing, which speeds up diagnosis for newborns.
In addition, the company is positioned to support large-scale genomic newborn screening programmes in the US and globally.
The acquisition also enables GeneDx to expand its commercial reach across EMEA, APAC, and LATAM, offering regulation-compliant AI-powered interpretation services.
Furthermore, the transaction unlocks recurring software-based revenue streams through Fabric’s interpretation-as-a-service model.
Fenwick & West served as legal advisor to GeneDx, while TD Cowen served as exclusive financial advisor and DLA Piper (US) as legal counsel to Fabric Genomics.
